Reviewing novel treatment options for carbapenem-resistant Enterobacterales

Keyphrases

• Novel Treatments 100%
• Carbapenem-resistant Enterobacterales 100%
• Metallo-β-lactamase 40%
• Enterobacteriaceae Infections 40%
• Novel Antimicrobials 30%
• Clinical Trials 20%
• β-lactamase Inhibitor 20%
• Enterobacterales 20%
• Beta-lactams 20%
• Treatment Strategy 10%
• Antibiotics 10%
• COVID-19 10%
• Treatment Options 10%
• Clinical Research 10%
• Conference Abstracts 10%
• PubMed 10%
• Literature Search 10%
• Inhibitor Combination 10%
• Area Cover 10%
• Global Health 10%
• Search Terms 10%
• Expert Opinion 10%
• New Antimicrobials 10%
• Antimicrobial Stewardship 10%
• Hospital-onset 10%
• Imipenem-cilastatin-relebactam 10%
• Meropenem-vaborbactam 10%
• Eravacycline 10%
• Plazomicin 10%
• Nacubactam 10%
• Zidebactam 10%
• Cefiderocol 10%
• Taniborbactam 10%
• Ceftazidime-avibactam 10%
• Major Threat 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Carbapenem 100%
• Penicillinase 60%
• Infection 50%
• Clinical Trial 20%
• Lactam 20%
• Antiinfective Agent 10%
• Clinical Research 10%
• Antibiotics 10%
• Cilastatin 10%
• Imipenem 10%
• Meropenem 10%
• Pandemic 10%
• Avibactam Plus Ceftazidime 10%
• Cefiderocol 10%
• Vaborbactam 10%
• Plazomicin 10%
• Zidebactam 10%
• Relebactam 10%
• Eravacycline 10%
• Nacubactam 10%